For the roughly 1 to 2 percent of pancreatic-cancer patients whose tumors carry a specific genetic glitch called KRAS G12C, treatment options after chemotherapy fails have been essentially nonexistent. That changed in late May 2026, when the FDA cleared the way for Revolution Medicines to open a formal expanded-access program for daraxonrasib, an oral targeted drug also known as RMC-6236. The program allows adults with metastatic pancreatic ductal adenocarcinoma (PDAC) and RAS mutations, including the G12C variant, to receive the investigational therapy even if they cannot enroll in the company’s ongoing Phase 3 clinical trial.
Pancreatic cancer remains one of the deadliest diagnoses in oncology. The five-year survival rate for metastatic disease hovers around 3 percent, according to the National Cancer Institute’s SEER database, and patients who progress through first-line chemotherapy typically face median survival measured in months. Nearly 90 percent of pancreatic tumors harbor mutations in the KRAS gene, but until recently no approved drug could effectively target the mutant protein. The G12C variant, while less common in pancreatic cancer than in lung cancer, has drawn particular attention because existing KRAS G12C inhibitors like sotorasib and adagrasib have shown that the mutation is druggable in other tumor types.
What the FDA authorized and who qualifies
Revolution Medicines disclosed the FDA’s “safe to proceed” determination in a company announcement, confirming that the agency reviewed the drug’s risk-benefit profile and concluded that broader access is justified for a seriously ill population with no satisfactory alternatives. The expanded-access treatment protocol is registered on ClinicalTrials.gov and will be available at multiple participating sites across the United States.
To qualify, patients must be adults with previously treated metastatic PDAC whose tumors carry RAS mutations, including KRAS G12C. They must also be unable to join a company-sponsored daraxonrasib trial, whether because enrollment at nearby sites has closed, geographic distance makes participation impractical, or comorbidities disqualify them under the strict criteria of a randomized study. In short, the program targets patients who have run out of standard options and would be reasonable candidates for the drug if a trial slot existed.
This is not the same as a one-off compassionate-use request, where a single physician petitions the FDA on behalf of an individual patient. Under the agency’s expanded-access regulations, a treatment protocol like this one allows a sponsor to distribute an investigational drug to a defined group under a unified plan. The FDA must determine that the potential benefit outweighs the risks, that the disease is serious or life-threatening, that no comparable approved therapy exists, and that expanded distribution will not compromise ongoing clinical research.
That last condition matters here. Revolution Medicines is running a large Phase 3 trial of daraxonrasib in the same patient population, and the FDA’s clearance signals that regulators believe both efforts can proceed without one undermining the other. The expanded-access program functions as a safety valve, not a shortcut around the pivotal study.
The clinical evidence behind the decision
Daraxonrasib is a RAS(ON) multi-selective inhibitor, meaning it targets the active form of multiple RAS-mutant proteins rather than a single variant. That broad mechanism is what makes it relevant to KRAS G12C patients as well as those with G12D, G12V, and other common KRAS alterations found in pancreatic cancer.
The FDA’s willingness to permit broader access before Phase 3 results are in hand rests on data from a first-in-human Phase 1/2 study (NCT05379985) that evaluated RMC-6236 in patients with advanced solid tumors harboring RAS mutations. Within the pancreatic-cancer cohort, investigators documented partial responses and durable disease control in a subset of heavily pretreated patients. The safety profile included gastrointestinal and hematologic side effects that were characterized as manageable in the context of metastatic PDAC. Results from this cohort were subsequently published in The New England Journal of Medicine, lending peer-reviewed credibility to the early signal.
Those findings propelled the drug into a registrational Phase 3 trial called RASolute 302 (NCT06625320), which randomizes patients with previously treated metastatic PDAC to daraxonrasib or standard-of-care therapy. The primary endpoints are progression-free survival and overall survival. The expanded-access program runs alongside this trial: patients in the program receive open-label daraxonrasib without randomization to a control arm, and their data will not carry the same evidentiary weight as results from the Phase 3 study.
Separately, Revolution Medicines received one of the FDA’s first National Priority Vouchers through the Commissioner’s pilot program, a designation meant to incentivize development in areas the agency considers especially urgent. In its first-quarter 2026 financial disclosure, the company reported that sites for both the Phase 3 trial and the expanded-access initiative are being activated.
What patients and oncologists still need to know
Several practical questions remain unanswered in public documents. Neither the FDA’s communication nor the ClinicalTrials.gov listing specifies a target enrollment number for the expanded-access program, so it is unclear whether the company will cap participation or scale it based on demand and drug supply. The full list of participating centers has not been published, which could limit access for patients in regions without a nearby site.
Because the program is just opening, no real-world safety or efficacy data from expanded-access patients have been collected yet. It will likely take months before clinicians can assess how the drug performs in a broader, less-selected population than the one enrolled in early-phase trials. Differences in performance status, organ function, and prior treatment history between expanded-access patients and trial participants could affect both the benefits and the risks.
Key scientific questions also linger. Publicly available information about RASolute 302 does not break out expected outcomes by specific KRAS variant in the comparator arm, so it is not yet possible to say whether G12C patients respond differently from those with G12D or G12V mutations. Understanding that distinction will be critical to defining daraxonrasib’s role if it reaches approval.
There is also an inherent tension whenever an expanded-access program operates alongside a registrational trial. For patients and their oncologists, guaranteed access to the investigational drug through the expanded program may look more appealing than the chance of being randomized to standard chemotherapy in the Phase 3 study. How Revolution Medicines manages that dynamic, through site selection, eligibility criteria, and communication with investigators, could shape both the pace of trial recruitment and the strength of the evidence that ultimately goes before regulators.
What this means for a cancer with few second chances
Expanded access is not approval. Daraxonrasib remains investigational, and the program does not guarantee that the drug will prove effective in a randomized setting. But for adults with metastatic PDAC who carry KRAS G12C or other RAS mutations and have exhausted standard chemotherapy, the program represents something that has been scarce in this disease: a molecularly targeted option and a reason to get tested for specific mutations that, until recently, were considered undruggable.
Patients interested in the program should talk to their oncologist about tumor genomic testing, confirm their KRAS mutation status, and ask whether their treatment center is a participating site or can refer them to one. As enrollment begins and early experiences accumulate, the oncology community will be watching to see whether daraxonrasib can deliver on the promise suggested by its early-phase data in one of cancer’s most difficult battlegrounds.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
